高级客户销售专员 - BCI BNP
快臻贸易（上海）有限公司
- 公司规模：50-150人
- 公司性质：外资（欧美）
- 公司行业：医疗设备/器械
职位信息
- 发布日期：2021-06-04
- 工作地点：成都
- 招聘人数：1人
- 工作经验：5-7年经验
- 学历要求：本科
- 语言要求：英语良好
- 职位月薪：1-1.5万/月
- 职位类别：医疗器械销售代表 医疗器械市场推广
职位描述
负责原Alere旗下（现被Quidel收购）心血管诊断产品线BCI BNP的区域销售。
主要工作职责Key Responsibilities:
1. 根据全国的新产品销售计划和区域市场的情况，执行公司的区域销售策略； 负责 BCI BNP产品线在当地市场的销售工作；
2. 完成区域销售指标，树立产品和公司的品牌形象；
3. 维护和开发区域专家；向医生传递和培训相关产品的信息，确保医生能深入了解公司产品特性；
4. 管理并培训相关的经销商，确保经销商团队对产品有深入了解。
任职条件Qualifications:
1. 本科或以上学历，医学检验与业优先考虑；或者临床、诊断背景；
2. 5年以上大型或合资器械企业的销售或售前应用或市场工作经验；
3. 扎实的检验领域知识；熟悉心血管领域优先；
4. 具有较好的医生教育知识和经验；
5. 优秀的分析，沟通及解决问题的能力。
公司介绍
Quidel Corporation (Nasdaq: QDEL) is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Quidel commenced operations in 1979 and launched its first products in 1984. Since that time, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular and Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Whether at our headquarters in San Diego, California, at our research and manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.
Quidel commenced operations in 1979 and launched its first products in 1984. Since that time, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular and Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Whether at our headquarters in San Diego, California, at our research and manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.
联系方式
- 公司地址：北京